The potential role of NT-proBNP in screening for and predicting prognosis in heart failure: A survival analysis

BMJ Open

Volumn 4, Issue 4, 2014, Pages

  Taylor, C J ^a   Roalfe, A K ^a   Iles, R ^a   Hobbs, F D R ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; HEART FAILURE; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SCREENING TEST; SURVIVAL; SURVIVAL TIME; AGED; BLOOD; CAUSE OF DEATH; FEMALE; MASS SCREENING; MIDDLE AGED; MORTALITY; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC;

AGED; BIOMARKERS; CAUSE OF DEATH; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MASS SCREENING; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROSPECTIVE STUDIES; ROC CURVE;

EID: 84899515726     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004675     Document Type: Article

References (22)

1. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-22. (Pubitemid 36936846)
2. Escobar C, Santiago-Ruiz JL, Manzano L. Diagnosis of heart failure in elderly patients: a clinical challenge. Eur J Heart Fail 2011;13:1152.
3. Ahmad T, O'Connor C. Therapeutic implications of biomarkers in chronic heart failure. Clin Pharmacol Ther 2013;94:468-79.
4. Mark DB, Felker GM. B-type natriuretic peptide - a biomarker for all seasons? N Engl J Med 2004;350:718-20. (Pubitemid 38364631)
5. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1347-51.
6. Mant J, Doust J, Roalfe A, et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess 2009;13:1-207.
7. Hobbs FD, Davis RC, Roalfe AK, et al. Reliability of N-terminal proBNP assay in diagnosis of left ventricular systolic dysfunction within representative and high risk populations. Heart 2004;90:866-70. (Pubitemid 39005929)
8. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-63. (Pubitemid 38364624)
9. Hartmann F, Packer M, Coats AJ, et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 2004;110:1780-6. (Pubitemid 39302655)
10. Svensson M, Gorst-Rasmussen A, Schmidt EB, et al. NT-pro-BNP is an independent predictor of mortality in patients with end-stage renal disease. Clin Nephrol 2009;71:380-6.
11. Davies M, Hobbs F, Davis R, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 2001;358:439-44. (Pubitemid 32769849)
12. Taylor CJ, Roalfe AK, Iles R, et al. Ten-year prognosis of heart failure in the community: follow-up data from the Echocardiographic Heart of England Screening (ECHOES) study. Eur J Heart Fail 2012;14:176-84.
13. Brandimarte F, Vaduganathan M, Mureddu GF, et al. Prognostic implications of renal dysfunction in patients hospitalised with heart failure: data from the last decade of clinical investigations. Heart Fail Rev 2013;18:167-76.
14. Januzzi JL, Chen-Tournoux AA, Moe G. Amino-terminal Pro-B-Type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol 2008;101(Suppl):29A-38A.
15. Guidelines for the diagnosis of heart failure. The task force on heart failure of the European Society of Cardiology. Eur Heart J 1995;16:741-51.
16. Dickstein K, Cohen-Solal A, Filippatos G, et al.; European Society of Cardiology, Heart Failure Association of the ESC (HFA), European Society of Intensive Care Medicine (ESICM). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-89.
17. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012;33:1787-847.
18. Ammar KA, Jacobsen SJ, Mahoney DW, et al. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation 2007;115:1563-70. (Pubitemid 46648641)
19. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-402. (Pubitemid 35239711)
20. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004;292:344-50. (Pubitemid 38944258)
21. National Institute of Health and Clinical Excellence. Chronic heart failure. Management of chronic heart failure in adults in primary and secondary care. NICE, 2010.
22. Fuat A, Murphy JJ, Hungin AP, et al. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract 2006;56:327-33.